(Q77052081)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

review article

1 reference

title

Direct vascular effects of HMG-CoA reductase inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

Lorenzo Arnaboldi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

Alberto Corsini

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

author name string

S Bellosta

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

F Bernini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

P Quarato

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

M Canavesi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

R Fumagalli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

R Paoletti

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

publication date

1 April 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

volume

137 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

page(s)

S101-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

The case for aggressive lipid regulation

2 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Management of primary hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 1. Structural modification of 5-substituted 3,5-dihydroxypentanoic acids and their lactone derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Meeting national cholesterol education goals in clinical practice--a comparison of lovastatin and fluvastatin in primary prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

HMG CoA reductase inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Regulation of the mevalonate pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Effect of lovastatin on intimal hyperplasia after balloon angioplasty: A study in an atherosclerotic hypercholesterolemic rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

The pathogenesis of atherosclerosis: a perspective for the 1990s

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Update on the pathogenesis of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

A modern view of atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Modification of atherosclerosis by agents that do not lower cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Pathogenesis of atherosclerosisand the role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Collagen types I and III, collagen content, GAGs and mechanical strength of human atherosclerotic plaque caps: span-wise variations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Matrix metalloproteinases and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Prenyl proteins in eukaryotic cells: a new type of membrane anchor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

p21ras is modified by a farnesyl isoprenoid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Vastatins Inhibit Tissue Factor in Cultured Human Macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Effect of pravastatin on outcomes after cardiac transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Posttranslational modification of proteins by isoprenoids in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900319-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0021-9150(97)00319-5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9694549%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

1 reference